Research Article Open Access

Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors

Madhu N. Rao1, Grace A. Lee1 and Carl Grunfeld1
  • 1 University of California at San Francisco, France

Abstract

The use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection and AIDS has been associated with multiple abnormalities in glucose and lipid metabolism. Specifically, these abnormalities include insulin resistance, increased triglycerides and increased LDL cholesterol levels. The metabolic disturbances are due to a combination of factors, including the direct effect of medications, restoration to health and HIV disease, as well as individual genetic predisposition. Of the available anti-retroviral medications, indinavir has been associated with causing the most insulin resistance and ritonavir with causing the most hypertriglyceridemia.

American Journal of Infectious Diseases
Volume 2 No. 3, 2006, 159-166

DOI: https://doi.org/10.3844/ajidsp.2006.159.166

Submitted On: 13 July 2006 Published On: 30 September 2006

How to Cite: Rao, M. N., Lee, G. A. & Grunfeld, C. (2006). Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors. American Journal of Infectious Diseases, 2(3), 159-166. https://doi.org/10.3844/ajidsp.2006.159.166

  • 3,807 Views
  • 2,663 Downloads
  • 15 Citations

Download

Keywords

  • HIV
  • glucose
  • lipids
  • protease inhibitor
  • antiretroviral